Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate

S. Palacios, I. Agodoa, S. Bonnick, J. van den Bergh, I. Ferreira, P.R. Ho, J.P. Brown

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Context: For many patients, adhering to postmenopausal osteoporosis treatment is a challenge. Higher treatment satisfaction is associated with greater persistence with these therapies, which is associated with better outcomes. Objective: To evaluate the change in treatment satisfaction in postmenopausal women who were suboptimally adherent to daily or weekly oral bisphosphonates and who transitioned to denosumab versus a monthly oral bisphosphonate Design: Pooled data from two international, multicenter, randomized, open-label studies Setting: Outpatient clinical setting Patients: 1703 postmenopausal women aged >/=55 years with low bone mineral density who were suboptimally adherent with prior oral bisphosphonate therapy, as assessed by the Osteoporosis-Specific Morisky Medication Adherence Scale Interventions: Denosumab, a fully human monoclonal antibody to RANKL, 60 mg subcutaneously every 6 months versus the oral bisphosphonates ibandronate or risedronate 150 mg once monthly for 12 months Main Outcome Measures: Change in treatment satisfaction scores from baseline to months 6 and 12 using the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM is a validated tool that measures perception of four domains of treatment satisfaction: effectiveness, side effects, convenience, and global satisfaction. Results: Patients in both treatment groups showed improvement from baseline for all four TSQM domains at 6 and 12 months. However, the denosumab group had significantly (all P<0.001) greater improvements among all four TSQM domains at 6 and 12 months compared with the oral bisphosphonate group. Conclusions: Women with low adherence to oral bisphosphonates reported greater treatment satisfaction when transitioned to denosumab versus switching to a monthly oral bisphosphonate.
Original languageEnglish
Pages (from-to)E487-E492
Number of pages6
JournalJournal of Clinical Endocrinology & Metabolism
Volume100
Issue number3
DOIs
Publication statusPublished - Mar 2015

Keywords

  • RANDOMIZED-OPEN-LABEL
  • ALENDRONATE THERAPY
  • FRACTURE RATES
  • OSTEOPOROSIS
  • DENSITY
  • IMPACT

Cite this